ESSA Pharma Analyst Ratings
ESSA Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 507.14% | Oppenheimer | → $17 | Reiterates | Outperform → Outperform |
| 06/26/2023 | 507.14% | Oppenheimer | → $17 | Assumes | → Outperform |
| 05/12/2022 | 614.29% | Piper Sandler | $50 → $20 | Maintains | Overweight |
| 08/17/2021 | 685.71% | Oppenheimer | $36 → $22 | Maintains | Outperform |
| 03/04/2021 | 1685.71% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
| 02/25/2021 | 1042.86% | HC Wainwright & Co. | $36 → $32 | Maintains | Buy |
| 02/11/2021 | 1185.71% | HC Wainwright & Co. | $17 → $36 | Maintains | Buy |
| 01/11/2021 | 507.14% | HC Wainwright & Co. | $10 → $17 | Maintains | Buy |
| 10/25/2019 | 185.71% | Oppenheimer | → $8 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 507.14% | 奧本海默 | →$17 | 重申 | 跑贏→跑贏大盤 |
| 2023/06/26 | 507.14% | 奧本海默 | →$17 | 假設 | →跑贏大盤 |
| 2022年05月12日 | 614.29% | 派珀·桑德勒 | $50→$20 | 維護 | 超重 |
| 2021/08/17 | 685.71% | 奧本海默 | $36→$22 | 維護 | 跑贏大盤 |
| 03/04/2021 | 1685.71% | 派珀·桑德勒 | →$50 | 開始承保 | →超重 |
| 02/25/2021 | 1042.86% | HC Wainwright公司 | $36→$32 | 維護 | 買 |
| 02/11/2021 | 1185.71% | HC Wainwright公司 | $17→$36 | 維護 | 買 |
| 2021/11/01 | 507.14% | HC Wainwright公司 | $10→$17 | 維護 | 買 |
| 2019年10月25日 | 185.71% | 奧本海默 | →$8 | 開始承保 | →跑贏大盤 |
What is the target price for ESSA Pharma (EPIX)?
ESSA Pharma(EPIX)的目標價是多少？
The latest price target for ESSA Pharma (NASDAQ: EPIX) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $17.00 expecting EPIX to rise to within 12 months (a possible 507.14% upside). 2 analyst firms have reported ratings in the last year.
奧本海默於2023年8月9日報道了ESSA Pharma(納斯達克：EPIX)的最新目標價。這家分析公司將目標價定為17美元，預計EPIX將在12個月內上漲至(可能上漲507.14%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for ESSA Pharma (EPIX)?
ESSA Pharma(EPIX)的最新分析師評級是多少？
The latest analyst rating for ESSA Pharma (NASDAQ: EPIX) was provided by Oppenheimer, and ESSA Pharma reiterated their outperform rating.
納斯達克(Sequoia Capital：EPIX)的最新分析師評級是由奧本海默提供的，ESSA Pharma重申了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for ESSA Pharma (EPIX)?
ESSA Pharma(EPIX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ESSA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ESSA Pharma was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與ESSA Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ESSA Pharma的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating ESSA Pharma (EPIX) correct?
分析師對ESSA Pharma(EPIX)的評級正確嗎？
While ratings are subjective and will change, the latest ESSA Pharma (EPIX) rating was a reiterated with a price target of $0.00 to $17.00. The current price ESSA Pharma (EPIX) is trading at is $2.80, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的ESSA Pharma(EPIX)評級被重申，目標價在0.00美元至17.00美元之間。ESSA Pharma(EPIX)目前的交易價格為2.80美元，在分析師的預測範圍內。